Adjuvant Iodine131 Lipiodol after Resection of Hepatocellular Carcinoma

Background. survival after liver resection for hcc is compromised by a high rate of intrahepatic recurrence. adjuvant treatment with a single,postoperative dose of intra-arterial i131 lipiodol has shown promise,as a means of prolonging disease-free survival (dfs). methodology. dfs and overall survival (os) after a single dose of postoperative i131 lipiodol were compared to liver resection alone,for treatment of hepatocellular carcinoma (hcc). data were collected retrospectively for patients who had a curative resection for hcc between december 1993 and september 2011. seventy-two patients were given i131 lipiodol after surgery and 70 patients had surgery alone. results. the dfs at 1,3,and 5 years was 72%,43%,and 26% in the surgery group and 70%,39%,and 29% in the adjuvant i131 lipiodol group (p=0.75). the 1-,3-,and 5-year os was 83%,64%,and 52% in the surgery group and 96%,72%,and 61% in the adjuvant i131 lipiodol group (p=0.16). conclusion. this retrospective study has found no significant benefit to survival,after adjuvant treatment with i131 lipiodol. © 2015 ruelan v. furtado et al.